HOOKIPA Pharma(US:HOOK)2019-11-22 12:01Company Strategy & Pipeline - HOOKIPA aims to overcome immune system underperformance with immunotherapies to prevent or cure infectious diseases and cancer[3] - The company's strategy involves achieving patient proof of concept by 2020, expanding the platform by 2024, and marketing therapeutics by 2027[9, 10] - HOOKIPA's pipeline includes HB-101 for CMV, HBV and HIV therapies, HB-201 and HB-202 for HPV16+ cancers, and HB-301 for prostate cancer, with anticipated milestones including preliminary data for HB-101 in H1 2020 and IND for HB-201 in H1 2019[11] Technology & Immunogenicity - Arenavirus technology can trigger >50% antigen-specific CD8+ T cells, demonstrating superior potency compared to other technologies[15] - HB-101 Phase 1 trial showed robust CD8+ and CD4+ T cell and CMV-neutralizing antibody responses, with no meaningful vector-neutralizing antibodies and a well-tolerated profile[23] - In the HB-101 Phase 1 trial, dose-dependent, durable CMV phosphoprotein 65 (pp65) specific CD8+ T cells were observed following 3 injections[25] Clinical Trials & Applications - HB-101 Phase 2 CMV trial is ongoing in solid organ transplantation patients, aiming for >50% reduction of viremia rate[29] - TheraT® can turn "cold" tumors "hot", with stronger tumor infiltration by cytotoxic T cells than adenovirus[32] - Pre-clinical trials show that sequential administration of TheraT® (PICV) & TheraT® (LCMV) increased anti-tumor activity and survival compared to single administration[43] Financials - For the nine months ended September 30, 2019, HOOKIPA reported $8.3 million in revenue from collaboration & licensing, R&D expenses of $35.1 million, G&A expenses of $11.1 million, and a net loss of $32.8 million[52] - As of September 30, 2019, HOOKIPA had $124.0 million in cash, cash equivalents and restricted cash, total assets of $152.0 million, total liabilities of $26.3 million, and equity and convertible preferred stock of $125.8 million[53]